Acute Social Anxiety Disorder Pipeline

DelveInsight’s, “Social Anxiety Disorder Pipeline Insight, 2026” report provides comprehensive insights about 11+ companies and 11+ pipeline drugs in Social Anxiety Disorder  pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Social Anxiety Disorder Understanding

Social Anxiety Disorder Overview

Social anxiety disorder (SAD), also known as social phobia, is a common and chronic mental health condition characterized by an intense and persistent fear of social or performance situations in which an individual may be exposed to scrutiny, judgment, or negative evaluation by others. People with SAD often experience excessive anxiety about being embarrassed, humiliated, or rejected, leading them to avoid social interactions or endure them with significant distress. The disorder can substantially impair academic, occupational, and interpersonal functioning, adversely affecting quality of life. Once considered a relatively rare condition, SAD is now recognized as one of the most prevalent anxiety disorders worldwide and often begins during childhood or adolescence.

The exact cause of social anxiety disorder is unknown, but it is thought to result from a combination of genetic, environmental, and neurobiological factors. A family history of anxiety disorders, stressful or negative social experiences, and alterations in brain regions involved in fear and emotional processing, particularly the amygdala, may contribute to the development of the disorder. Based on current evidence, SAD is considered a multifactorial condition arising from the interaction of these factors.

The pathophysiology of social anxiety disorder involves abnormal activity in brain circuits that regulate fear and emotional responses. Hyperactivity of the amygdala and altered signaling of neurotransmitters such as serotonin, dopamine, and GABA may contribute to excessive fear, anxiety, and heightened sensitivity to social situations. 

Social anxiety disorder is diagnosed through clinical assessment based on a persistent fear of social situations, significant distress or functional impairment, and symptoms lasting for at least six months. The diagnosis is made using established diagnostic criteria after ruling out other potential causes of the symptoms.

Treatment of social anxiety disorder (SAD) typically includes psychotherapy and pharmacotherapy. Cognitive behavioral therapy (CBT) is considered a first-line treatment and helps individuals identify and modify negative thought patterns and behaviors associated with social anxiety. Medications such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are also commonly used to reduce symptoms and improve daily functioning.

"Social Anxiety Disorder Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Social Anxiety Disorder  pipeline landscape is provided which includes the disease overview and Social Anxiety Disorder  treatment guidelines. The assessment part of the report embraces, in depth Social Anxiety Disorder  commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Social Anxiety Disorder  collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Social Anxiety Disorder Pipline Report Highlights 

The companies and academics are working to assess challenges and seek opportunities that could influence Social Anxiety Disorder  R&D. The therapies under development are focused on novel approaches to treat/improve Social Anxiety Disorder . 

Social Anxiety Disorder  Emerging Drugs Analysis

This segment of the Social Anxiety Disorder  report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Social Anxiety Disorder Emerging Drugs

BNC210: Neuphoria Therapeutics Inc.

BNC210 is an investigational oral anxiolytic developed for the treatment of Social Anxiety Disorder (SAD). The drug has a novel mechanism of action as a selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor (α7 nAChR). By modulating α7 nAChR signaling, BNC210 is designed to reduce hyperactivity in neural circuits involved in fear and anxiety responses without causing the sedation, cognitive impairment, or dependency commonly associated with traditional anxiolytics such as benzodiazepines. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Social Anxiety Disorder.

NTX-1472: Newleos Therapeutics, Inc.

NTX-1472 is a novel investigational therapy being developed for the treatment of Social Anxiety Disorder (SAD). The drug is a highly selective, brain-penetrant vasopressin 1a (V1a) receptor antagonist that blocks the action of arginine vasopressin (AVP), a neuropeptide involved in regulating anxiety, stress responses, and social-threat processing. V1a receptors are highly expressed in brain regions associated with fear and social behavior, including the central amygdala, lateral septum, and bed nucleus of the stria terminalis. By inhibiting V1a signaling, NTX-1472 is designed to directly target the neural circuits underlying social anxiety, potentially offering a differentiated treatment approach with improved tolerability compared with existing serotonergic therapies. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Social Anxiety Disorder.

Further product details are provided in the report……..

Social Anxiety Disorder Drug Therapeutic Assessment

This segment of the report provides insights about the different Social Anxiety Disorder  drugs segregated based on following parameters that define the scope of the report, such as:

Major Social Anxiety Disorder Players in Social Anxiety Disorder

There are approx. 11+ key companies which are developing the therapies Social Anxiety Disorder . The companies which have their Social Anxiety Disorder  drug candidates in the most advanced stage, i.e. Phase III include Neuphoria Therapeutics Inc., and others.

Social Anxiety Disorder Clinical Trial Phases

DelveInsight’s report covers around 11+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Social Anxiety Disorder Drug Route of Administration

Social Anxiety Disorder  pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal 
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Social Anxiety Disorder Product Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Social Anxiety Disorder Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Social Anxiety Disorder Clinical Trial Activities 

The Social Anxiety Disorder Pipeline report provides insights into different Social Anxiety Disorder Clinical Trial within phase II, I, preclinical and discovery stage. It also analyses Social Anxiety Disorder therapeutic drugs key players involved in developing key drugs. 

Social Anxiety Disorder Pipeline Development Activities

The Social Anxiety Disorder Clinical Trial Analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Social Anxiety Disorder drugs.

Social Anxiety Disorder Report Insights

• Social Anxiety Disorder  Pipeline Analysis
• Social Anxiety Disorder Therapeutic Assessment
• Social Anxiety DisorderUnmet Needs
• Impact of Social Anxiety DisorderDrugs

Social Anxiety Disorder Report Assessment

• Social Anxiety Disorder Pipeline Product Profiles
• Social Anxiety Disorder Therapeutic Assessment
• Social Anxiety Disorder Pipeline Assessment
• Social Anxiety Disorder Inactive drugs assessment
• Social Anxiety Disorder Market Unmet Needs

Key Questions Answered in the Social Anxiety Disorder Pipeline Report

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Social Anxiety Disorder  drugs?
• How many Social Anxiety Disorder  drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Social Anxiety Disorder ?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Social Anxiety Disorder  therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Social Anxiety Disorder  and their status?
• What are the key designations that have been granted to the emerging drugs?

Social Anxiety Disorder Key Players

• Neuphoria Therapeutics Inc.
• Newleos Therapeutics, Inc.
• Ono pharmaceutical Co., Ltd.
• Exxel pharmaceuticals

Social Anxiety Disorder Key Products

• BNC210
• NTX-1472
• ONO-1110
  EXL14280